Baseline characteristics
| ADX+NIVO n=72 | NIVO only n=72 | |
| Age, median years (range) | 61 (25–80) | 62 (23–80) |
| Male, n (%) | 49 (68) | 50 (69) |
| White race, n (%) | 55 (76) | 61 (85) |
| Screening ECOG PS, n (%) | ||
| 0 | 23 (32) | 24 (33) |
| 1 | 48 (66) | 45 (63) |
| Missing | 1 (1) | 3 (4) |
| Primary tumor site, n (%) | ||
| Gastric | 40 (56) | 33 (46) |
| Proximal | 19 (26) | 14 (19) |
| Distal | 21 (29) | 19 (26) |
| GEJ | 30 (42) | 35 (49) |
| Other | 2 (3) | 4 (6) |
| Differentiation, n (%) | ||
| Well differentiated | 6 (9) | 2 (3) |
| Moderately differentiated | 21 (29) | 29 (40) |
| Poorly differentiated | 35 (49) | 21 (29) |
| Undifferentiated | 1 (1) | 0 |
| Other | 0 | 1 (1) |
| Unknown | 9 (13) | 19 (26) |
| Prior chemotherapy regimens, n (%) | ||
| 1 | 28 (39) | 29 (40) |
| 2 | 20 (28) | 19 (26) |
| 3+ | 24 (33) | 24 (33) |
| PD-L1 ≥1% TC, n (%) | 13 (18) | 13 (18) |
| PD-L1 ≥1% TC+IC, n (%) | 52 (72) | 52 (72) |
| dMMR, n (%) | 0 | 3 (4) |
ADX, andecaliximab; dMMR, mismatch repair deficiency; ECOG, Eastern Cooperative Oncology Group; GEJ, gastroesophageal junction; NIVO, nivolumab; PD-L1, programmed death ligand 1; TC+IC, tumor and associated immune cell-positive.